Free Trial
NASDAQ:EVO

Evotec (EVO) Stock Price, News & Analysis

$3.42
+0.06 (+1.79%)
(As of 03:49 PM ET)

About Evotec Stock (NASDAQ:EVO)

Key Stats

Today's Range
$3.39
$3.44
50-Day Range
$2.96
$4.80
52-Week Range
$2.85
$12.00
Volume
31,439 shs
Average Volume
107,184 shs
Market Capitalization
$1.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Hold

Company Overview

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Evotec Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
42nd Percentile Overall Score

EVO MarketRank™: 

Evotec scored higher than 42% of companies evaluated by MarketBeat, and ranked 668th out of 1,000 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Evotec has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Evotec has only been the subject of 3 research reports in the past 90 days.

  • Read more about Evotec's stock forecast and price target.
  • Earnings Growth

    Earnings for Evotec are expected to grow in the coming year, from ($0.34) to ($0.03) per share.

  • Price to Book Value per Share Ratio

    Evotec has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.10% of the float of Evotec has been sold short.
  • Short Interest Ratio / Days to Cover

    Evotec has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Evotec has recently increased by 42.01%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Evotec does not currently pay a dividend.

  • Dividend Growth

    Evotec does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.10% of the float of Evotec has been sold short.
  • Short Interest Ratio / Days to Cover

    Evotec has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Evotec has recently increased by 42.01%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Evotec has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Evotec this week, compared to 3 articles on an average week.
  • Search Interest

    Only 8 people have searched for EVO on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Evotec insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.00% of the stock of Evotec is held by insiders.

  • Percentage Held by Institutions

    Only 5.81% of the stock of Evotec is held by institutions.

  • Read more about Evotec's insider trading history.
Receive EVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

EVO Stock News Headlines

Evotec (NASDAQ:EVO) Shares Gap Down - What's Next?
Short Interest in Evotec SE (NASDAQ:EVO) Rises By 42.0%
Biden to Launch “FedNOW” [Move Your Money Now]
Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...
Evotec (NASDAQ:EVO) Sees Large Volume Increase
DAX Rallies As China Steps Up Economic Support
See More Headlines

EVO Stock Analysis - Frequently Asked Questions

Evotec's stock was trading at $11.73 at the beginning of 2024. Since then, EVO shares have decreased by 70.8% and is now trading at $3.42.
View the best growth stocks for 2024 here
.

Evotec (EVO) raised $435 million in an initial public offering on Thursday, November 4th 2021. The company issued 20,000,000 shares at a price of $21.75 per share.

Shares of EVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Today
10/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EVO
Employees
5,061
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$8.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+104.7%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$788.44 million
Cash Flow
$0.03 per share
Book Value
$3.42 per share

Miscellaneous

Free Float
350,827,000
Market Cap
$1.21 billion
Optionable
Not Optionable
Beta
1.41
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:EVO) was last updated on 10/4/2024 by MarketBeat.com Staff
From Our Partners